Related references
Note: Only part of the references are listed.Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich et al.
LANCET (2021)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2020)
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2020)
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
Alice B. Gottlieb et al.
DERMATOLOGY AND THERAPY (2020)
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Jillian Frieder et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
Tom C. Chan et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Biological Properties and the Role of IL-25 in Disease Pathogenesis
Yuwan Liu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
David Pariser et al.
DERMATOLOGY AND THERAPY (2018)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
A. Blauvelt et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
Peter Bhoi et al.
BMJ OPEN (2017)
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis
Sophie Glatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Benjamin Farahnik et al.
DERMATOLOGY AND THERAPY (2016)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Effect of IL-17A blockade with secukinumab in autoimmune diseases
Dhavalkumar D. Patel et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
Machaon Bonafede et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
Andrew Johnston et al.
JOURNAL OF IMMUNOLOGY (2013)
Dosing Frequency and Medication Adherence in Chronic Disease
Craig I. Coleman et al.
JOURNAL OF MANAGED CARE PHARMACY (2012)
Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
Elizabeth A. Brezinski et al.
PLOS ONE (2012)